ADHD drug SPN-812 tested for Long-Term safety in children
NCT ID NCT02736656
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study investigates the long-term safety and effectiveness of SPN-812 (viloxazine) in children and adolescents with ADHD. Participants who completed a prior SPN-812 study can continue taking the medication once daily for up to 72 months. The trial includes children aged 4–17 years and monitors side effects and symptom changes over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- viloxazine extended-release capsules (SPN-812)
- What this could lead to
- If successful, this could confirm viloxazine as a safe long-term treatment option for managing ADHD symptoms in children and adolescents.
- What could go wrong
- This is an open-label extension study without a placebo group, so results may be less reliable. Long-term side effects are still being monitored.
Why investors are watching
Supernus Pharmaceuticals is running a Phase 3 open-label extension study of SPN-812, its ADHD drug for children, in 1,400 patients. This trial tests long-term safety and efficacy, which matters because regulators and doctors need years of data before the drug can become a standard treatment. For a small company, this readout can determine whether SPN-812 becomes a reliable revenue source or remains an unproven product.
If it works: If the trial shows the drug stays safe and effective over the long term, Supernus could gain a stronger position in the pediatric ADHD market. That result might support regulatory approval and encourage wider use, which would help the company grow.
If it fails: If the trial reveals safety problems or weak long-term efficacy, the drug's future could be in doubt. Clinical trials often fail, and a negative result here could hurt the company's prospects and delay any potential approval.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 1,400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2016
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Cohort 'A' Inclusion/Exclusion Criteria: Inclusion Criteria 'A': 1. Completion of a previous blinded study of SPN-812 for the treatment of ADHD. 2. Continues to be medically healthy and with clinically normal laboratory profiles, vital signs, and electrocardiograms (ECGs). 3. Weight of at least 20 kg if 6-11 years old and at least 35 kg if 12 years or older. 4. Written Informed Consent obtained from the subject's parent or legally authorized representative (LAR); and written Informed Assent obtained from the subject if appropriate; written Informed Consent obtained from the subject if he/she is 18 years old. 5. Females of Childbearing Potential (FOCP) must be either sexually inactive (abstinent) or, if sexually active, must agree to use one of the following acceptable birth control methods beginning 30 days prior to the first dose, throughout the study: 1. simultaneous use of male condom and intra-uterine contraceptive device placed at least four weeks prior to the first study drug administration 2. surgically sterile male partner 3. simultaneous use of male condom and diaphragm with spermicide 4. established hormonal contraceptive Exclusion Criteria 'A': 1. Current diagnosis of significant systemic disease or of a major psychiatric or neurological disorder, including history or family history of seizures or seizure-like disorders. History of Major Depressive Disorder is allowed if the subject is free of episodes currently and for the last six months. 2. Current evidence of suicidal ideation and/or behaviors (assessed with Columbia Suicide Severity Rating Scale or C-SSRS). 3. Body Mass Index (BMI) greater than 95th percentile for the appropriate age and gender (according to the CDC BMI-for-Age Growth Charts for boys and girls). 4. Pregnancy, breastfeeding, or refusal to practice contraception during the study for female subjects of childbearing potential (FOCP). 5. Current substance or alcohol use. 6. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study. Cohort 'B' Inclusion/Exclusion Criteria: Inclusion Criteria 'B': 1. Has completed a previous Study 812P401 and is less than 6 years of age at Visit 1 in this study (812P310). 2. Continues to be medically healthy with clinically normal laboratory profiles, vital signs, and electrocardiograms. 3. Weighs at least ≥5th percentile for age and sex. 4. Parent or LAR is willing and able to provide Written Informed Consent. Exclusion Criteria 'B': 1. Has a current diagnosis of significant systemic disease and/or of a major psychiatric or neurological disorder. 2. Current evidence of suicidal ideation and/or behaviors (assessed with Columbia Suicide Severity Rating Scale or C-SSRS), is at significant risk of suicide, either in the opinion of the Investigator or defined as a "yes" to suicidal ideation C-SSRS questions 4 or 5 or answering "yes" to suicidal behavior on the C-SSRS at Visit 1 or has attempted suicide from day of end of study in previous blinded study to day of Visit 1 in this study (812P310). 3. Has a BMI \>95th percentile for the appropriate age and sex (according to the CDC BMI-for-Age Growth Charts for boys and girls). 4. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Attention deficit hyperactivity disorder are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alliance for Wellness dba Alliance for Research
Long Beach, California, 90807, United States
-
Bayou City Research Corporation
Houston, Texas, 77006, United States
-
CNS Healthcare
Memphis, Tennessee, 38119, United States
-
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, 38119, United States
-
Ericksen Research & Development
Clinton, Utah, 84015, United States
-
Florida Clinical Research Center, LLC
Maitland, Florida, 32751, United States
-
Florida Clinical Research Center, LLC.
Maitland, Florida, 32751, United States
-
IPS Research
Oklahoma City, Oklahoma, 73103, United States
-
Indago Research & Health Center, Inc.
Hialeah, Florida, 33012, United States
-
MCB Clinical Research Centers, LLC
Colorado Springs, Colorado, 80910, United States
-
Meridien Research at Florida Clinical Research Center
Bradenton, Florida, 34201, United States
-
Northwest Clinical Trials
Bellevue, Washington, 98004, United States
-
Paradigm Research Professionals
Oklahoma City, Oklahoma, 73118, United States
-
Road Runner Research
San Antonio, Texas, 78258, United States
-
Sarkis Clinical Trials
Gainesville, Florida, 32607, United States
-
Woodland International Research Group
Little Rock, Arkansas, 72211, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could hidden ADHD symptoms be dragging down medical Students' grades?
- Can virtual worlds teach Real-Life social skills to kids with ADHD?
- Disaster-Proofing ADHD: a parent training program to the test
- Can tailored school support boost behavior and language in kids with ADHD?
- Could a gentle massage at bedtime help kids with ADHD sleep?
- Do weighted blankets unlock better sleep for kids with ADHD?